Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
<p>Choroideremia is a rare, X-linked retinal degeneration resulting in progressive vision loss. A randomized, masked, phase 3 clinical trial evaluated the safety and efficacy over 12 months of follow-up in adult males with choroideremia randomized to receive a high-dose (1.0&thi...
Главные авторы: | MacLaren, RE, Fischer, MD, Gow, JA, Lam, BL, Sankila, E-MK, Girach, A, Panda, S, Yoon, D, Zhao, G, Pennesi, ME |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Springer Nature
2023
|
Схожие документы
-
Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
по: Han, RC, и др.
Опубликовано: (2021) -
Recent advances and future prospects in choroideremia
по: Zinkernagel MS, и др.
Опубликовано: (2015-11-01) -
Macular hole surgery in patients with end-stage choroideremia
по: Zinkernagel, MS, и др.
Опубликовано: (2013) -
Functional defects in color vision in patients with choroideremia
по: Jolly, J, и др.
Опубликовано: (2015) -
Choroideremia: molecular mechanisms and development of AAV gene therapy
по: Patrício, M, и др.
Опубликовано: (2018)